Houston health orgs lost $58M in canceled, stalled NIH grants, new report shows

research cuts

The Science & Community Impacts Mapping Project identified 37 cancelled or frozen NIH grants for Houston institutions. Photo via Unsplash.

Seven institutions in the Houston area have lost nearly $60 million in grants from the National Institutes of Health (NIH) that were aimed at funding health research.

The Science & Community Impacts Mapping Project identified 37 cancelled or frozen NIH grants worth $58.7 million that were awarded to seven Houston-area institutions. The University of Texas Medical Branch at Galveston suffered the biggest loss — five grants totaling nearly $44.8 million.

The Harvard University T.H. Chan School of Public Health reported in May that over the previous several months across the U.S., the federal government had terminated roughly 2,100 NIH research grants worth around $9.5 billion.

In August, the U.S. Supreme Court derailed researchers’ efforts to reinstate almost $2 billion in research grants issued by NIH, according to Nature.com.

“Make no mistake: This was a decision critical to the future of the nation, and the Supreme Court made the wrong choice. History will look upon these mass National Institutes of Health (NIH) research grant terminations with shame,” the American Association of Medical Colleges said in a statement. “The Court has turned a blind eye to this grievous attack on science and medicine, and we call upon Congress to take action to restore the rule of law at NIH.”

Texas health researchers rely heavily on NIH grants and contracts. During the federal government’s 2024 budget year, NIH awarded $1.9 billion in grants and contracts that directly supported 30,553 jobs and more than $6.1 billion in economic activity in Texas, according to the United for Medical Research coalition.

Here’s a rundown of the cancelled and frozen NIH grants in the Houston area.

  • University of Texas Medical Branch at Galveston: Five cancelled or frozen grants, totalling approximately $44.8 million in funding lost.
  • Baylor College of Medicine: 17 grants cancelled or frozen, totalling approximately $8 million in funding lost
  • University of Houston. Five cancelled or frozen grants, totalling approximately $3.7 million in funding lost
  • University of Texas Health Science Center Houston: Five grants cancelled or frozen, totaling approximately $1.1 million in funding lost.
  • University of Texas MD Anderson Cancer Center: Two grants cancelled or frozen, totalling $831,581 in funding
  • Rice University. Two grants cancelled or frozen, totaling $254,645 in funding lost
  • Prairie View A&M University: One grant cancelled or frozen, totalling $31,771 in funding lost
From Your Site Articles
MD Anderson is teaming up with TOPPAN Holdings on cutting-edge organoid tech to help match cancer patients with the most effective treatments. Photo via Getty Images.

MD Anderson launches $10M collaboration to advance personalized cancer treatment tech

fighting cancer

The University of Texas MD Anderson Cancer Center and Japan’s TOPPAN Holdings Inc. have announced a strategic collaboration to co-develop TOPPAN Holdings’ 3D cell culture, or organoid, technology known as invivoid.

The technology will be used as a tool for personalized cancer treatments and drug screening efforts, according to a release from MD Anderson. TOPPAN has committed $10 million over five years to advance the joint research activities.

“The strategic alliance with MD Anderson paves a promising path toward personalized cancer medicine," Hiroshi Asada, head of the Business Innovation Center at TOPPAN Holdings, said in a news release.

Invivoid is capable of establishing organoid models directly from patient biopsies or other tissues in a way that is faster and more efficient. Researchers may be able to test a variety of potential treatments in the laboratory to understand which approach may work best for the patient, if validated clinically.

“Organoids allow us to model the three-dimensional complexity of human cancers in the lab, thus allowing us to engineer a powerful translational engine—one that could not only predict how patients will respond to therapy before treatment begins but also could help to reimagine how we discover and validate next-generation therapies," Dr. Donna Hansel, division head of pathology and laboratory medicine at MD Anderson, added in the news release. “Through this collaboration, we hope to make meaningful progress in modeling cancer biology for therapeutic innovation.”

The collaboration will build upon preclinical research previously conducted by MD Anderson and TOPPAN. The organizations will work collaboratively to obtain College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certifications for the technology, which demonstrate a commitment to high-quality patient care. Once the certifications are obtained, they plan to conduct observational clinical studies and then prospective clinical studies.

“We believe our proprietary invivoid 3D cell culture technology, by enabling the rapid establishment of organoid models directly from patient biopsies, has strong potential to help identify more effective treatment options and reduce the likelihood of unnecessary therapies,” Asada added in the release. “Through collaboration on CAP/CLIA certification and clinical validation, we aim to bring this innovation closer to real-world patient care and contribute meaningfully to the advancement of cancer medicine."

Fannin Partners and the University of Texas MD Anderson Cancer Center have teamed up to develop drugs based on Raptamer, the creation of Fannin company Radiomer Therapeutics. Photo via Getty Images

Exclusive: 2 Houston health care institutions team up to develop cancer-fighting treatments

collaboration station

Two Houston organizations announced a new collaboration in a major move for Houston’s biotech scene.

Fannin Partners and the University of Texas MD Anderson Cancer Center have teamed up to develop drugs based on Raptamer, the creation of Fannin company Radiomer Therapeutics.

“Raptamers combine antibody level affinities with desirable physical and pharmacokinetic properties, and a rapid path to clinic,” Dr. Atul Varadhachary, CEO of Radiomer Therapeutics and Fannin managing partner, Varadhachary, explained to InnovationMap in May. “We are deploying this unique platform to develop novel therapies against attractive first-in-class oncology targets.”

The pairing of Fannin and MD Anderson makes perfect sense. Researchers at the institution have already identified novel markers that they will target with both Raptamer-based drugs and radiopharmaceutical/radioligand therapies.

“MD Anderson and Fannin bring highly complementary capabilities to the identification of novel cancer targets and Raptamer-based drug discovery,” says Varadhachary in a press release. “Our collaboration will enable us to rapidly develop targeted therapeutics against novel targets, which we hope will offer hope to patients with progressive cancers.”

Early in this meeting of minds, researchers will focus on developing targeted radiopharmaceuticals — the Radiomers for which Varadhachary’s company is named — as well as targeted drug conjugates that utilize Raptamers. Raptamers are an innovative class of targeting vectors that combine a DNA oligonucleotide backbone with added peptide functionality, for oncology indications.

“We are committed to exceptional research that can help us further our understanding of cancer and develop impactful therapeutic options for patients in need,” says Timothy Heffernan, Ph.D., vice president and head of therapeutics discovery at MD Anderson. “Fannin’s Raptamer drug discovery platform represents an innovative new modality that offers the potential to enhance our portfolio of novel therapies, and we look forward to the opportunities ahead.”

Fannin and MD Anderson will design translational studies together and collaborate to select promising targets for drug discovery. This is a great deal for Fannin, which will retain commercialization rights for the assets that are developed. But MD Anderson won’t be left out; the institution is eligible to receive some payments based on the success of Radiomers and other Raptamer-based drugs developed through the collaboration.

Earlier this year, Varadhachary joined the Houston Innovators Podcast to discuss Fannin's innovation approach and contribution to medical development in Houston. Listen to the episode below.

MD Anderson Cancer Center received $3 million to establish a new genomics research hub. Photo by F. Carter Smith/Courtesy of MD Anderson

Houston hospital to establish genomics research hub as part of CPRIT's $60M round of grants

coming soon

Houston’s University of Texas MD Anderson Cancer Center will create a genomics research hub thanks to a nearly $3 million award from the Cancer Prevention and Research Institute of Texas, or CPRIT.

“This groundbreaking facility will have a profound impact on cancer research, and improving the diagnosis and treatment of cancer patients in Texas,” says CPRIT.

CPRIT gave the monetary award to Nicholas Navin, a professor at MD Anderson and at the biomedical sciences school within the University of Texas Health Science Center at Houston (UTHealth Houston).

The new facility will specialize in advanced spatial genomics, which creates a three-dimensional “atlas” that’s been dubbed “the Google Map of the human body,” according to CPRIT.

“Spatial genomics is an exciting new field that allows cancer researchers to directly connect the images of cells and their tissue structures with genomic data while preserving the spatial context,” CPRIT explains. “This provides the researchers with the ability to see exactly where distinct types of cells are located within a tumor, and determine the genes and proteins they are expressing.”

Until recently, most genomic technologies such as DNA and RNA sequencing required scientists to “grind up” tumor tissues to extract molecules for analysis, according to CPRIT.

“This process means losing the complex composition of the different cell types and their spatial arrangement within the tumor, which makes it difficult to understand the complex environment of cancer cells,” the institute adds.

MD Anderson’s new genomics hub will feature tissue processing, slide imaging, spatial genomics technologies, and spatial data analysis methods for cancer researchers within the Texas Medical Center and around the state.

In other CPRIT funding news, three local medical institutions received a total of $8 million for recruitment of four cancer researchers.

MD Anderson received half of the $8 million from CPRIT. The money will go toward bring aboard:

  • Hojong Yoon. Yoon, recipient of a $2 million scholar recruitment award, is a postdoctoral student at the Cambridge, Massachusetts-based Broad Institute. The institute, affiliated with Harvard University and MIT, is a research organization. Yoon’s research focuses on targeted cancer therapy.
  • Marianna Trakala. Trakala, recipient of a $2 million scholar recruitment award, is a postdoctoral researcher at MIT’s Koch Institute for Integrative Cancer Research. She is studying how small conditional RNA (scRNA) causes a response that triggers activation of the immune system and elimination of cancer cells from tissue.

The Baylor College of Medicine and the University of Texas Health Science Center at Houston (UTHealth Houston) each received one $2 million scholar recruitment award:

  • Louai Labanieh, a postdoctoral researcher at Stanford University’s Parker Institute for Cancer Immunotherapy, is joining the Baylor College of Medicine. Labanieh’s research involves engineering next-generation cells to improve cancer immunotherapy.
  • Yanjun Sun, a neuroscientist who is a postdoctoral scholar at Stanford, is joining UTHealth Houston.

In all, CPRIT recently doled out more than $60 million for cancer-fighting efforts around the state. Aside from the Baylor College of Medicine, MD Anderson, and UTHealth Houston, Rice University and Texas Southern University received CPRIT funding.

“By supporting the vital core facilities that researchers need, funding groundbreaking research, and deepening the bench of clinical trial investigators, CPRIT is fulfilling the promise central to our mission: We are helping Texans conquer cancer,” says Kristen Doyle, CEO of CPRIT.

MD Anderson broke ground on a 600,000 square-foot building that is specifically designed to enable great minds to meet with the goal of conquering cancer. Photo courtesy of MD Anderson

Houston-based, cancer-fighting organization breaks ground on new collaborative building

ready to rise

Houston is where medical researchers and clinicians come together. And it’s getting easier for that to happen thanks to an innovative new facility from The University of Texas MD Anderson Cancer Center.

On September 20, the world-class institution broke ground on a 600,000 square-foot building that is specifically designed to enable great minds to meet with the goal of conquering cancer.

Construction on the seven-story structure, known as South Campus Research Building 5 (SCRB5), is supported by a $668 million institutional grant. The facility is expected to be completed in 2026. Designed by Elkus Manfredi Architects, it will include both high-tech research rooms and public spaces that include a restaurant, conference center and spaces for lectures. A landscaped park is designed by Mikyoung Kim Design.

“The construction of our visionary new research building marks the beginning of our next chapter in Making Cancer History,” Peter WT Pisters, M.D., president of MD Anderson, says in a press release. “With input from hundreds of MD Anderson teammates, we have carefully designed this building and our research campus to foster collaboration, to stimulate creativity and to fuel breakthroughs that will improve the lives of patients here and around the globe.”

SCRB5 is located at 1920 Spanish Trail and is considered an extension of upcoming Helix Park, Texas Medical Center’s 5 million square-foot research campus. Both are specifically designed to create seamless collaborations between scientists and clinicians, where water cooler chat can lead to world-changing discoveries. MD Anderson has already announced that the building will be home to a number of strategic research programs, including the James P. Allison Institute.

The new construction isn’t just notable for the discoveries that will be made there. In itself, SCRB5 will be an exceptionally sustainable and efficient building, with surrounding green spots and connecting pathways that will serve as inspiration for all who work there. This only makes sense for MD Anderson, which invested $1.1 billion in funding in the last fiscal year. In the same year, the institution had more projects funded by the National Cancer Institute than any other.

Rendering courtesy of MD Anderson

Six Houston inventors have been recognized with the highest professional distinction for inventors within academia. Photo via Pexels

6 Houston-area inventors named fellows in prestigious program

best in class

The National Academy of Inventors has announced its annual set of NAI Fellows — and six Houstonians make the list of the 164 honorees from 116 research institutions worldwide.

The NAI Fellows Program honors academic inventors "who have demonstrated a spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on the quality of life, economic development, and the welfare of society," according to a news release. The appointment is the highest professional distinction for inventors within academia.

The six Houstonians on the list join a group that hold more than 48,000 U.S. patents, which have generated over 13,000 licensed technologies and companies, and created more than one million jobs, per the release. Additionally, $3 trillion in revenue has been generated based on NAI Fellow discoveries.

These are the scientists from Houston organizations:

    • Zhiqiang An, University of Texas Health Science Center at Houston: An is the director of the Texas Therapeutics Institute, a drug discovery program operated by the John P. and Kathrine G. McGovern Medical School at Houston. He's also a professor of molecular medicine and holder of the Robert A. Welch Distinguished University Chair in Chemistry at UTHealth.
    • Alex Ignatiev, University of Houston: Ignatiev served as director of two NASA-supported research and technology development centers at the University of Houston and as Lillie Cranz and Hugh Roy Cullen Professor of Physics, Chemistry, and Electrical and Computer Engineering.
    • David Jaffray, University of Texas MD Anderson Cancer Center: Jaffray was appointed MD Anderson's first-ever chief technology and digital officer in 2019. He oversees MD Anderson’s Information Services division and Information Security department and is a professor of Radiation Physics with a joint appointment in Imaging Physics.
    • Pei-Yong Shi,The University of Texas Medical Branch: Pei-Yong Shi is a professor and John Sealy Distinguished Chair in Innovations in Molecular Biology Department of Biochemistry & Molecular Biology;. He's also the Vice Chair for Innovation and Commercialization.
    • Ganesh Thakur, University of Houston: Thakur is a pioneer in carbon capture, utilization and storage and has a patent on forecasting performance of water injection and enhanced oil recovery. His team is continuing to push the research envelope for CCUS employing world-class lab research, simulation, machine learning and artificial intelligence.
    • Darren Woodside, Texas Heart Institute: Woodside is the Vice President for Research and Director of the Flow Cytometry and Imaging Core at the Texas Heart Institute. His research centers around the role that cell adhesion plays in cardiovascular and autoimmune diseases, and the development of novel means to identify and treat these diseases.
    Ten other Texas-based innovators made the list, including:
    • Sanjay Banerjee, The University of Texas at Austin
    • Thomas Boland, The University of Texas at El Paso
    • Joan Brennecke, The University of Texas at Austin
    • Gerard Cote, Texas A&M University
    • Ananth Dodabalapur, The University of Texas at Austin
    • Holloway (Holly) H. Frost Jr., The University of Texas at Arlington
    • James E. Hubbard, Texas A&M University
    • Yi Lu, University of Texas at Austin
    • Samuel Prien, Texas Tech University
    • Earl E. Swartzlander Jr., The University of Texas at Austin
    This year's class will be inducted at the Fellows Induction Ceremony at the 11th Annual Meeting of the National Academy of Inventors in June in Phoenix, Arizona.

    "The caliber of this year's class of NAI Fellows is outstanding. Each of these individuals are highly-regarded in their respective fields," says Paul R. Sanberg, president of NAI's board of directors, in the release. "The breadth and scope of their discovery is truly staggering. I'm excited not only see their work continue, but also to see their knowledge influence a new era of science, technology, and innovation worldwide."

    Ad Placement 300x100
    Ad Placement 300x600

    CultureMap Emails are Awesome

    Property Showcase

    Houston ranks No. 2 for share of AI talent in professional services

    AI surge

    Houston’s professional and business services sector—think law, accounting, consulting, and engineering firms—grabs one of the industry’s biggest shares of AI talent.

    A report from commercial real estate services giant CBRE ranks Houston No. 2 among the top 50 U.S. and Canadian tech markets for the concentration of AI talent in professional and business services.

    Houston’s share of AI talent in professional and business services stands at 26 percent, the report shows. Washington, D.C., tops the list at 31 percent. At 25 percent, Dallas-Fort Worth claims the No. 3 spot.

    CBRE based the AI ranking on data from the LinkedIn networking platform.

    The company’s researchers tallied 11,709 AI-related tech jobs in Houston. Nationwide, data scientists lead AI-related job growth in the U.S., according to the report.

    “AI software and hardware developers are currently the most sought-after tech talent by employers,” the report says.

    Houston faces AI talent gap

    DoubleTrack, a provider of AI and data consulting, reported in June that Houston faces an AI talent gap.

    “The places where businesses say they will adopt AI over the next six months, well ahead of where they are today, are mostly the same places already short on talent: Miami, Houston, and Denver among the metros, South Dakota and South Carolina among the states,” DoubleTrack said.

    This labor shortage comes amid Houston’s ascent as an AI hub. For instance, a factory being built here by AI chipmaker NVIDIA and electronics manufacturer Foxconn will produce AI supercomputers and infrastructure systems.

    Houston’s place in the sphere of tech talent

    Overall, Houston ranks No. 32 in the CBRE report among the top 50 U.S. and Canadian markets for tech talent. The San Francisco Bay Area claims the top spot, with Austin at No. 5 and DFW at No. 8.

    CBRE relied on 13 metrics to rank tech talent markets, including concentration of tech talent, tech talent pipeline, and research-and-development investments.

    Here are other Houston details from the report:

    • In 2025, Houston’s tech talent workforce numbered 104,080, up 7.3 percent over the past three years.
    • Houston’s average wage for tech talent within the tech industry was $120,216 in 2025, up 13.3 percent over the past three years.

    New pilot program for air taxis, Project Nexus, takes flight in Texas

    Project Nexus

    By 2029, Texas skies could be buzzing with air taxis, much like they are with drones today.

    To kick off the "Project Nexus" pilot program in Texas, U.S. Transportation Secretary Sean Duffy, U.S. Sen. Ted Cruz, and Texas Department of Transportation officials attended an event September 10 at Fort Worth Alliance Airport, which serves as the launchpad for a statewide pilot program that could result in air taxis, self-piloted planes, and vertical take-off-and-landing aircraft permanently buzzing across the skies of Texas.

    It was the first demonstration in Texas of next-generation aircraft under the pilot program; Texas is the sixth state to participate in the program.

    Air taxi service on the radar
    The federal government has teamed up with aviation companies BETA Technologies and Joby Aviation, as well as the Texas Department of Transportation, to develop regional air taxi service in Dallas, Austin, San Antonio, and eventually Houston.

    Roger Venables, Fort Worth’s aviation director, said in January that he foresees regular air taxi service becoming a reality in the next five years.

    On September 12, a Joby-made electric air taxi took a roundtrip flight between Fort Worth Alliance and Dallas Fort Worth International Airport to test flight operations.

    The mission was part of a five-day test involving Fort Worth Alliance and DFW Airport flights, and flights over the Fort Worth Stockyards, Toyota Motor North America’s Plano headquarters, and other sites.

    A new facility at Fort Worth Alliance will be Joby’s long-term home for regional flight operations.

    Building a 'framework' for electric aircraft
    TxDOT said Project Nexus is aimed at creating “a scalable system” to connect urban areas, rural communities, and neighboring states as air mobility technology advances.

    In a TxDOT release, Marc Williams, the agency’s executive director, said the pilot program will “build a framework for how electric aircraft could one day connect people, goods, and communities across the state.”

    Three-phase project will test flight capabilities

    Initial flights in the third-year pilot program won’t carry passengers, according to TxDOT. Instead, the flights will gather data, validate air travel routes, and help improve the safety of air mobility technology.

    The first phase of the U.S. Department of Transportation’s Project Nexus will feature piloted aircraft such as helicopters and fixed-wing planes. CultureMap previously reported Plano-based VertiPorts by Atlantic, which develops takeoff and landing sites for airplane-helicopter hybrids, would be part of Project Nexus.

    The second phase will involve testing airborne medical and cargo logistics. This includes transporting critical medical supplies or donor organs between rural and urban hospitals in the Austin and San Antonio areas.

    In the third and final phase, passengers will fly aboard air taxis across the Texas Triangle. Dallas-Fort Worth, Austin, Houston, and San Antonio anchor the triangle.

    “In Texas, we don’t wait for the future to arrive, we build it,” Cruz said in the TxDOT release. “The Lone Star State is pushing the boundaries by testing the next generation of aircraft through Project Nexus.”

    “These technologies will connect communities, expand access to jobs and services, and strengthen supply chains,” the senator added. “What starts in Texas will help shape the future of aviation throughout the entire country.”

    ---

    This article originally appeared on CultureMap.com.

    Houston-area NASA contractor plans Nasdaq IPO

    going public

    Webster-based NASA contractor Rothe Development Inc. has filed paperwork with the U.S. Securities and Exchange Commission to go public.

    Rothe, a minority- and woman-owned business, hasn’t yet identified how many shares it will sell and how much money its IPO might raise. Rothe plans to offer Class B common stock on the Nasdaq exchange.

    CEO Karen Wheeler-Hall owns all of the Class A shares and would retain majority control after the IPO, according to the SEC filing. The company plans to use $2.4 million of the IPO proceeds so Wheeler-Hall can pay off a loan from the seller for her 2021 acquisition of Rothe.

    From last December to this May, the company raised about $2.1 million in a pre-IPO private placement at $1 per share, the SEC filing shows.

    Rothe runs NASA training lab in Houston

    Founded in 1967, Rothe supplies engineering, technology, operations and technical services to NASA, the U.S. Department of Defense, other federal agencies, commercial space operators, and regulated industries.

    Rothe is likely best known for operating NASA’s Neutral Buoyancy Laboratory in Houston. The lab trains astronauts for spacewalks and simulates space missions. It supports NASA’s International Space Station and Artemis programs.

    Company sees room for growth

    In the SEC filing, Rothe said it operates in several expanding markets driven by rising investments, including space exploration, national security, cybersecurity and digital infrastructure.

    “We believe these market trends create significant opportunities for continued growth across both government and commercial sectors,” the company said.

    Rothe generated nearly $126.4 million in revenue last year, up from $117.3 million the previous year. However, the company swung to a $700,000 operating loss in 2025 versus $1.8 million in operating income in 2024.

    At the end of 2025, Rothe’s workforce comprised 385 employees and 25 subcontractors. The company also works in the cybersecurity, computer engineering, software development, multimedia and communication, and commercial calibration sectors, according to its website.

    View All Listings